沙利度胺联合多西他赛对激素抵抗性前列腺癌患者的免疫功能影响

The Effect of Thalidomide Combined with Docetaxel on Immune Function in Patients with Hormone Refractory Prostate Cancer

目的:观察沙利度胺联合多西他赛对激素抵抗性前列腺癌患者免疫功能的影响。方法:收集宜春市人民医院自2010年1月-2015年1月收治的激素抵抗性前列腺癌患者48例,随机分为两组,各24例。治疗组采用沙利度胺联合多西他赛,对照组采用多西他赛联合泼尼松,观察两组临床疗效、近期不良反应、生活质量以及免疫功能的改善。结果:治疗组患者的近期疗效、生活质量、免疫功能均明显改善,不良反应明显减少,与对照组比较差异均有统计学意义(P<0.05);治疗组的生存时间长于对照组,差异有统计学意义(P=0.046)。结论:沙利度胺联合多西他赛有效缓解激素抵抗性前列腺癌进展,沙利度胺能提高患者免疫力,减少化疗的不良反应,取得满意效果,值得临床推广。

Objective：To observe the effect of thalidomide combined with docetaxel on immunity of patients with hormone refractory prostate cancer.Method：48 patients diagnosed with hormone refractory prostate cancer were collected at the People’s Hospital of Yichun city from January 2010 to January 2015,they were randomly divided into two groups,24 cases in each group.The treatment group（Thalidomide combined with Docetaxel） and control group（Predisone combined with Docetaxel）,the clinical effects,short-term adverse reaction,quality of life and improvement of immune function in the two groups were observed.Result：The clinical effect, quality of life and immune function of the treatment group improved significantly,and the side effects decreased significantly,there were significant differences compared to control group（P〈0.05）.The survival time of the treatment group than the control group, the difference was statistically significant （P=0.046）.Conclusion：Thalidomide combined with Docetaxel effectively alleviate the progression of hormone refractory prostate cancer,Thalidomide can improve the patients immune system,reduce the side effect of chemotherapy,and obtain satisfactory effect,which is worth of popularizing.